<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VINORELBINE TARTRATE</span><br/>(vin-o-rel'been)<br/><span class="topboxtradename">Navelbine<br/></span><b>Classifications:</b> <span class="classification">antineoplastic agent</span>; <span class="classification">mitotic inhibitor</span><br/><b>Prototype: </b>Vincristine<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>A semisynthetic vinca alkaloid with antineoplastic activity. Inhibits polymerization of tubules into microtubules, which disrupts
         mitotic spindle formation. Neurotoxicity is less than with other vinca alkaloids (e.g., vincristine).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Arrests mitosis at metaphase, thereby, inhibiting cell division in cancer cells.</p>
<h1><a name="uses">Uses</a></h1>
<p>Non-small cell lung cancer.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Breast cancer, ovarian cancer, Hodgkin's disease.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to vinorelbine, pregnancy (category D), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to vincristine or vinblastine; infection, leukopenia, or other indicator(s) of bone marrow suppression; chickenpox
         or herpes zoster infection; hepatic insufficiency; preexisting neurologic or neuromuscular disorders. Safety and efficacy
         in children are not established.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Non-Small Cell Lung Cancer, Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 30 mg/m<sup>2</sup> weekly<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Use caution to prevent contact with skin, mucous membranes, or eyes during preparation.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 10 mg in a syringe with either 2 or 5 mL of D5W or NS to yield 3 mg/mL or 1.5 mg/L, respectively.  <span class="methodtype">IV Infusion:</span> Dilute the 10 mg/mL dose in an IV bag with D5W, NS, or RL to a final concentration of 0.52 mg/mL (example: 10 mg diluted
                  in 19 mL yields 0.5 mg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Give diluted solution over 610 min into the side port closest to an IV bag with free-flowing IV solution; follow by
                  flushing with at least 75125 mL of IV solution over 10 min. Take every precaution to avoid extravasation. If suspected,
                  discontinue IV immediately and begin in a different site.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Acyclovir,</b>
<b>aminophylline/theophylline,</b>
<b>amphotericin B,</b>
<b>ampicillin,</b>
<b>cefoperazone,</b>
<b>ceforanide,</b>
<b>cefotetan,</b>
<b>ceftriaxone,</b>
<b>fluorouracil,</b>
<b>furosemide,</b>
<b>ganciclovir,</b>
<b>methylprednisolone,</b>
<b>mitomycin,</b>
<b>piperacillin,</b>
<b>sodium bicarbonate,</b>
<b>thiotepa,</b>
<b>trimethoprimsulfamethoxazole.</b>
<span class="incompattype">Y-site:</span>
<b>Acyclovir,</b>
<b>allopurinol,</b>
<b>aminophylline/theophylline,</b>
<b>amphotericin B,</b>
<b>amphotericin B cholesteryl complex,</b>
<b>ampicillin,</b>
<b>cefazolin,</b>
<b>cefoperazone,</b>
<b>ceforanide,</b>
<b>cefotetan,</b>
<b>ceftriaxone,</b>
<b>fluorouracil,</b>
<b>furosemide,</b>
<b>ganciclovir,</b>
<b>methylprednisolone,</b>
<b>mitomycin,</b>
<b>piperacillin,</b>
<b>sodium bicarbonate,</b>
<b>thiotepa,</b>
<b>trimethoprimsulfamethoxazole.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 2°8° C (36°46° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Decreased deep tendon reflexes, paresthesia, fatigue, asthenia, peripheral neuropathy,</span> myalgia, jaw pain. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Anemia,</span>
<span class="speceff-both">neutropenia, granulocytopenia</span>, thrombocytopenia. <span class="typehead">GI:</span> Paralytic ileus, <span class="speceff-common">constipation, nausea, vomiting, diarrhea,</span> stomatitis, mucositis, hepatotoxicity <span class="speceff-common">(elevated LFT)</span>. <span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Pain on injection,</span> venous pain, thrombophlebitis, <span class="speceff-common">alopecia,</span> myalgia, muscle weakness. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased severity of granulocytopenia in combination with <b>cisplatin;</b> increased risk of acute pulmonary reactions in combination with <b>mitomycin;</b>
<b>paclitaxel</b> may increase neuropathy. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 6080% bound to plasma proteins (including platelets and lymphocytes); sequestered in tissues, especially lung, spleen,
      liver, and kidney, and released slowly. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted primarily in bile and feces (50%), 10% excreted in urine. <span class="typehead">Half-Life:</span> 4245 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor CBC with differential throughout therapy and on the day of treatment prior to each infusion. Monitor kidney
            &amp; liver functions and serum electrolytes periodically.
         </li>
<li>Withhold drug and notify physician if the granulocyte count is below 1000 cells/mm<sup>3</sup>.
         </li>
<li>Monitor for S&amp;S of infection, especially during period of granulocyte nadir 710 d after dosing.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of potential and inevitable adverse effects.</li>
<li>Notify physician of distressing adverse effects, especially symptoms of leukopenia (e.g., chills, fever, cough) and peripheral
            neuropathy.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>